Please assess the completion status of the following clinical trial:

Trial Title: Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~1. All patients must sign an informed consent~2. All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) must meet the following spirometric criteria:~a post-bronchodilator forced expiratory flow in 1 second (FEV1) =\<30% of predicted normal and \<80% of predicted normal and a post bronchodilator FEV1 / forced vital capacity (FVC) \<70% at Visit 1 4. Male or female patients, 40 years of age or older. 5. Patients must be current or ex-smokers with a smoking history of more than 10 pack years~Exclusion criteria:~* Patients with a significant disease other than COPD;~* Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis;~* Patients with a history of asthma or a total blood eosinophil count \>=600/mm3.~* Patients with any of the following conditions:~a diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists) a diagnosis of paroxysmal tachycardia - Patients with any of the following conditions: a history of myocardial infarction within 1 year of screening visit a diagnosis of clinically relevant cardiac arrhythmia a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~* Patients who have undergone thoracotomy with pulmonary resection~* Patients being treated with the following concomitant medications:~medications that prolong the QT/QTc interval oral Beta-adrenergics oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day~- Pregnant or nursing women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- olodaterol (BI 1744) low and placebo (Type: EXPERIMENTAL): low dose inhaled olodaterol orally once daily from the Respimat inhaler
- olodaterol (BI 1744) low and low tio (Type: EXPERIMENTAL): low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
- olodaterol (BI 1744) low and medium tio (Type: EXPERIMENTAL): low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
- olodaterol (BI 1744) low and high tio (Type: EXPERIMENTAL): low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
- olodaterol (BI 1744) high and placebo (Type: EXPERIMENTAL): high dose inhaled olodaterol orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) high and low tio (Type: EXPERIMENTAL): high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
- Olodaterol (BI 1744) high and medium tio (Type: EXPERIMENTAL): high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
- Olodaterol (BI 1744) high and high tio (Type: EXPERIMENTAL): high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).